We served as lead counsel for King Pharmaceuticals, Inc. and its board of directors in shareholder class actions relating to the $3.6 billion buyout of King by Pfizer, Inc.

King Pharmaceuticals (NYSE: KG) is a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world’s 39th largest pharmaceutical company.